Icon

XOFIGO (nda203971)- (162mCi/6ML (27mCi/ML))

RADIUM RA-223 DICHLORIDE BAYER HLTHCARE
162mCi/6ML (27mCi/ML)
No No
2027-Mar-23 2018-May-15
None None
None No
Xofigo is an alpha particle-emitting radioactive therapeutic agent indicated for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease.
0 0 0
Total Other Developers None
Drugs with Suitability No
162mCi/6ML (27mCi/ML) ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.